&w=3840&q=100)
Pharma manufacturing tends to cause AMR in communities: Nick Voulvoulis
Sohini Das Mumbai
Listen to This Article
Nick Voulvoulis is professor of environmental technology at the Centre for Environmental Policy, Imperial College, London. He has collaborated with Indian institutions for research that uncovered the link between antibiotic manufacturing in the country and the rise of antimicrobial resistance (AMR). Voulvoulis, in an email interview with Sohini Das, explained how low-cost antibiotics pressure manufacturers to spend on costly waste disposal. Edited excerpts:
Which AMR research projects are you working on?
I led a project called AMRWatch, which was one of five funded projects under the India-UK Tackling AMR in the Environment from Antimicrobial Manufacturing Waste programme funded by the
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
25 minutes ago
- Time of India
Healthcare costs in US to shoot up following Trump tariff on Indian goods: Industry experts
New Delhi: Healthcare costs in the US will increase following the imposition of sweeping 25 per cent tariff plus an unspecified penalty on Indian goods, experts from pharmaceuticals and medical devices industry said on Thursday. President Donald Trump on Wednesday announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty for buying Russian crude oil and military equipment. Explore courses from Top Institutes in Please select course: Select a Course Category healthcare Project Management Finance Technology Operations Management Artificial Intelligence Data Science Management PGDM Data Science Product Management Degree Others Healthcare Public Policy Design Thinking Cybersecurity Digital Marketing others CXO Leadership MCA MBA Data Analytics Skills you'll gain: Duration: 11 Months IIM Lucknow CERT-IIML Healthcare Management India Starts on undefined Get Details Profits for Indian pharmaceutical firms may decline and research and development may stagnate. However, for the medical devices sector as long as the gap between duty on China and India is over 15- 20 per cent, there are positive prospects for exports to the US, according to experts. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Top 15 Most Beautiful Women in the World Undo "India isn't just a key supplier of generics to the US. We are a part of the backbone of affordable global healthcare. These duties may interrupt the smooth trade flow, inflate US drug costs, stall treatments, and put even greater pressure on American healthcare budgets," OmniActive Health Technologies Executive Chairman and MD Sanjaya Mariwala said. On the other hand, he said, "Back home, the profits for Indian pharmaceutical firms may decline, and R&D may stagnate, slowing down innovation and stalling new drug clearances." Live Events AiMeD (Association of Indian Medical Device Industry) Forum Coordinator Rajiv Nath said, "Duties impact for Indian medical devices sector has to be seen from relative competitiveness - as long as duty gap between Chinese versus Indian is over 15- 20 per cent, we have positive prospects to export to USA and even put production lines in USA." Currently Indonesia and Vietnam have lower duties by 6 per cent. So for products made there they will possibly enjoy a price competitive advantage over India, he added. Stating that clarity will come after August 12 as then duties on Chinese goods will be clear, Nath said, "They were increased to over 50 per cent but temporarily reduced to 30 per cent. If post-August duties on Chinese medical devices revert to over 50 per cent and on Indian at 25 per cent, the export prospects versus China are in our favour..." He further said, "Suffice to say that whatever is the final duty that is finally announced on medical devices, if it's at least 15-20 per cent lower than applicable duty rates by US onto China then there is a strong opportunity for Indian medical devices to increase their exports to US market, if they are able to absorb the excessive high cost of regulatory approval of USFDA for market entry and find that these costs to export are sustainable over the years." However, he said, the government of India and manufacturers will need to work to improve India's competitiveness "so that we can offset the 6 per cent disadvantage over Indonesian and Vietnam competitors". Grant Thornton Bharat Partner and Tax Controversy Management Leader Manoj Mishra pointed out that the strong language used by President Trump and ongoing investigations into drug imports mean that the risk is not over yet. "Indian pharma companies should stay prepared for possible changes, especially if sector-specific duties are introduced later. That said, these tariffs are likely to be in place only for a short period, as both countries are expected to fast-track discussions for a Bilateral Trade Agreement. A balanced and stable trade deal will be key to protecting long-term interests of the sector," he noted. Similarly, Choice Broking Equity Research Analyst- Pharma Sector, Maitri Sheth said the US remains heavily reliant on India for its pharmaceutical needs, with about 50 per cent of generic drugs sourced from India. "Given the critical nature of healthcare and already elevated healthcare costs in the US, we view the likelihood of material near-term tariffs on pharma as low," Sheth added. While the headline risk persists, the structural dependence on Indian pharma and the cost sensitivity of the US healthcare system provide a strong case against aggressive tariff action on the sector, Sheth added. Medical Technology Association of India (MTaI) Chairman Pavan Choudary said President Trump's is "troubling and seems economically shortsighted and strategically misguided".
Time of India
an hour ago
- Time of India
Jitendra Malik's education path: This Indian-origin AI expert went from IIT Kanpur to Stanford, then pioneered machine vision at UC Berkeley
Indian-origin AI expert, Jitendra Malik In the bustling town of Mathura, India, a young boy named Jitendra Malik found himself captivated by puzzles, patterns, and the invisible logic of the world. That boy would one day help teach machines to see. His journey from school classrooms in Jabalpur to the elite laboratories of UC Berkeley, has become a roadmap for aspiring students in both India and abroad. But Malik's story is not just one of academic success. It's about how the power of education—when matched with vision and curiosity, can reshape an entire field. IIT Kanpur : Where genius took flight Jitendra Malik's academic odyssey truly took flight when he earned admission into the Indian Institute of Technology (IIT) Kanpur, one of India's premier engineering institutions. By the time he graduated in 1980, he wasn't just another engineer, rather he was the gold medalist, recognised as the best in his class in electrical engineering. IIT Kanpur provided Malik with more than a rigorous education, it gave him exposure to cutting-edge thought and global ambition. It was here that his interest in systems, computation, and intelligence deepened—foreshadowing a future in artificial intelligence. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Kafr Salim: Unsold Sofas Prices May Surprise You (Prices May Surprise You) Sofas | Search Ads Search Now Undo The AI spark ignites at Stanford After IIT, Malik set his sights westward and joined Stanford University for a PhD in Computer Science. He arrived in California in the early 1980s, just as the digital revolution was beginning to take root. At Stanford, Malik immersed himself in the world of computer vision, an emerging field that asked a fundamental question: Can we teach machines to see like humans? He pursued that question with vigor, completing his PhD in 1985 and helping lay the foundations for the next generation of visual computing. Innovation and mentorship at UC Berkeley In 1986, Malik joined the faculty of the University of California, Berkeley, where he remains to this day as the Arthur J. Chick Professor in Electrical Engineering and Computer Sciences. Over nearly four decades, Malik has pioneered breakthroughs in computer vision, graphics, and machine learning. Concepts such as anisotropic diffusion, shape context, normalised cuts, and R-CNN, now cornerstones of image recognition and AI, emerged from his research group. Malik didn't stop at research. He's also mentored over 60 PhD students and postdoctoral fellows, many of whom now teach and lead in top institutions like MIT, Caltech, CMU, and Cornell. His influence has cascaded across generations of AI thinkers. Leading research in the tech frontier In 2018, Malik took on a new role as Research Director at Facebook AI Research (FAIR) in Menlo Park, California. There, he leads a team pushing the boundaries of computer vision, robotics, and machine learning, helping bridge the gap between academic theory and real-world AI systems. His move reflects a larger trend: world-class researchers shaping not just academic thought, but the technology that powers modern life. A legacy etched in citations Jitendra Malik is one of the most cited computer scientists in the world, with over 150,000 citations and multiple prestigious awards, including the IEEE Computer Pioneer Award, the IJCAI Research Excellence Award, and fellowships from IEEE, ACM, and the National Academy of Sciences. But perhaps his greatest legacy lies in his story of how education at IIT Kanpur and Stanford equipped him not just with knowledge, but with the tools to pioneer, to question, and to lead. Jitendra Malik's journey shows that a solid foundation, combined with relentless curiosity, can carry a student from small-town India to the global stage of AI. His path isn't just a personal success story; it's a blueprint for how education can shape not only a career but an entire field. For today's students dreaming of building future technologies, Malik's life offers a powerful reminder: where you begin doesn't limit where you can go, especially when learning leads the way. TOI Education is on WhatsApp now. Follow us here . Ready to navigate global policies? Secure your overseas future. Get expert guidance now!
Hans India
2 hours ago
- Hans India
Agilent Supports India's Global Biopharma Ambitions with State-of-the-Art Experience Center in Hyderabad
Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, today announced the inauguration of its new Biopharma Experience Center in Hyderabad, Telangana. The facility marks a significant investment in India's rapidly growing life sciences ecosystem and reflects Agilent's long-term commitment to advancing biopharmaceutical innovation both locally and globally. The center was inaugurated by Shri Duddila Sridhar Babu, Hon'ble Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana, in the presence of Agilent President and CEO Padraig McDonnell, along with senior leaders from India's pharmaceutical and biopharma sectors. The new Agilent Biopharma Experience Center in Hyderabad presents a major opportunity to accelerate the city's leadership in life sciences and healthcare innovation. Designed to support the full drug development journey, the center brings together advanced lab technologies, expert training, and regulatory-ready workflows to help researchers, scientists, and companies develop high-quality, life-saving medicines faster and more efficiently. It offers end-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis, and lab informatics, allowing companies to simulate real lab environments, test for quality and compliance, and co-create market-ready solutions tailored to both Indian and global needs. For Hyderabad's vibrant ecosystem of startups, academic institutions, and skilled professionals, the center unlocks direct access to global expertise, cutting-edge instrumentation, and real-world application environments. It supports faster R&D, hands-on training aligned with international regulatory standards, and stronger collaboration between industry and academia. By addressing critical challenges in biosimilars, biologics, and precision medicine, the facility strengthens Hyderabad's position as a trusted global hub for next-generation drug development, and a key contributor to India's biopharma growth story. 'India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation,' said Padraig McDonnell, CEO, Agilent Technologies. 'Our future will be defined by continued innovation and a relentless focus on our customers. This new center reflects our commitment to delivering integrated solutions that help bring life-changing therapies to market faster and more efficiently. It also reinforces our support for the 'Make-in-India' initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions.' Located in the heart of India's life sciences capital, the center is designed to address critical gaps in analytical capabilities and regulatory readiness for biopharma companies. It will serve as a hub for innovation and collaboration, supporting the development of biologics, biosimilars, and precision medicine. Shri Duddila Sridhar Babu, Hon'ble Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana said, 'Hyderabad has emerged as a complete healthcare and life sciences ecosystem—from drug discovery and clinical trials to world-class hospitals and affordable, high-quality patient care. We are proud to host eight of the top ten global pharma companies, five of India's leading healthcare chains, and over 230 USFDA-approved manufacturing facilities. Contributing nearly one-third of India's pharmaceutical production and 40% of bulk drug exports, Telangana is making a strong impact both nationally and globally. With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system. The launch of the Agilent Biopharma Experience Center is a significant milestone in strengthening Telangana's position as a global leader in life sciences, and a valuable addition to our expanding innovation-driven ecosystem.' Hyderabad offers one of the most mature and future-focused life sciences ecosystems in India, combining deep industry expertise, strong R&D capabilities, and a supportive policy environment. With its legacy in generics and a growing focus on advanced therapies, the city is well-positioned for the next phase of healthcare innovation. The launch of the Agilent Biopharma Experience Center builds on this foundation, introducing advanced analytical and regulatory capabilities that support both local innovation and global delivery. This capital investment is part of Agilent's broader three-to-five-year India growth strategy, which includes expanding its footprint, deepening customer partnerships, and positioning India as a strategic hub in Agilent's global innovation and profitability roadmap. The India Solution Center in Manesar, launched earlier this year, further reflects this ongoing commitment—contributing to Agilent's efforts to enhance its presence and capabilities in one of its fastest-growing, high-priority markets globally. 'Agilent is already working closely with many of India's leading biopharma companies,' added McDonnell. 'With this center, we aim to strengthen those relationships and co-create solutions that meet the evolving needs of the Indian and global markets.' This milestone marks a new chapter in Agilent's journey with India—deepening collaboration, accelerating innovation, and contributing to a healthier, more sustainable future.
